(EHTH) eHealth - Overview
Stock: Medicare Plans, Individual Plans, Ancillary Products, Marketplace Platform
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 79.3% |
| Relative Tail Risk | -19.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.19 |
| Alpha | -100.15 |
| Character TTM | |
|---|---|
| Beta | 1.581 |
| Beta Downside | 1.322 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.07% |
| CAGR/Max DD | -0.47 |
Description: EHTH eHealth January 19, 2026
eHealth, Inc. (NASDAQ:EHTH) runs a U.S.-focused health-insurance marketplace that connects consumers with Medicare and non-Medicare plans, offering education, enrollment tools, and post-enrollment support through a suite of branded websites (eHealth.com, eHealthInsurance.com, eHealthMedicare.com, Medicare.com, GoMedigap.com).
The business is split into two segments: (1) **Medicare**, which sells Medicare Advantage, Supplement, Part D, and ancillary products (dental, vision) and provides advertising services to plan sponsors; and (2) **Employer & Individual**, which markets individual, family, and small-business health plans plus ancillary coverage, primarily to non-Medicare-eligible customers.
Beyond plan sales, eHealth monetizes its e-commerce platform through lead referrals, technology licensing, non-broker-of-record arrangements, and post-enrollment services, positioning itself as a data-driven decision-support hub that aggregates and presents plan information in an objective format for comparison and purchase.
**Key market signals:** (i) FY 2023 revenue reached roughly **$1.1 billion**, up about **12 % YoY**, driven by higher Medicare enrollment and increased digital acquisition spend; (ii) the U.S. Medicare-eligible population is projected to grow **~5 % annually** over the next decade, expanding the addressable market; (iii) the broader online health-insurance brokerage sector is expected to compound at **~8 % CAGR** through 2026, reflecting consumer shift toward digital enrollment and the regulatory push for price transparency.
For a deeper quantitative view, the ValueRay platform offers a granular financial model and scenario analysis that can help you assess eHealth’s upside potential.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 50.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 0.70 > 1.0 |
| NWC/Revenue: 46.34% < 20% (prev 61.74%; Δ -15.39% < -1%) |
| CFO/TA -0.02 > 3% & CFO -17.1m > Net Income 50.3m |
| Net Debt (29.6m) to EBITDA (71.6m): 0.41 < 3 |
| Current Ratio: 5.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.6m) vs 12m ago 3.89% < -2% |
| Gross Margin: 85.96% > 18% (prev 1.00%; Δ 8496 % > 0.5%) |
| Asset Turnover: 52.99% > 50% (prev 46.40%; Δ 6.59% > 0%) |
| Interest Coverage Ratio: 5.71 > 6 (EBITDA TTM 71.6m / Interest Expense TTM 10.0m) |
Altman Z'' 1.53
| A: 0.24 (Total Current Assets 302.9m - Total Current Liabilities 51.2m) / Total Assets 1.05b |
| B: -0.04 (Retained Earnings -43.8m / Total Assets 1.05b) |
| C: 0.06 (EBIT TTM 57.2m / Avg Total Assets 1.02b) |
| D: -0.27 (Book Value of Equity -43.9m / Total Liabilities 162.9m) |
| Altman-Z'' Score: 1.53 = BB |
Beneish M -2.74
| DSRI: 0.88 (Receivables 210.3m/203.5m, Revenue 543.0m/464.9m) |
| GMI: 1.16 (GM 85.96% / 99.76%) |
| AQI: 1.09 (AQ_t 0.70 / AQ_t-1 0.64) |
| SGI: 1.17 (Revenue 543.0m / 464.9m) |
| TATA: 0.06 (NI 50.3m - CFO -17.1m) / TA 1.05b) |
| Beneish M-Score: -2.74 (Cap -4..+1) = A |
What is the price of EHTH shares?
Over the past week, the price has changed by -21.55%, over one month by -47.27%, over three months by -42.49% and over the past year by -77.51%.
Is EHTH a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EHTH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.5 | 282.9% |
| Analysts Target Price | 8.5 | 282.9% |
| ValueRay Target Price | 1.5 | -33.3% |
EHTH Fundamental Data Overview February 03, 2026
P/E Forward = 2.7933
P/S = 0.1604
P/B = 0.1711
P/EG = 0.7211
Revenue TTM = 543.0m USD
EBIT TTM = 57.2m USD
EBITDA TTM = 71.6m USD
Long Term Debt = 69.4m USD (from longTermDebt, last quarter)
Short Term Debt = 7.77m USD (from shortTermDebt, last quarter)
Debt = 92.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 29.6m USD (from netDebt column, last quarter)
Enterprise Value = 104.5m USD (87.1m + Debt 92.7m - CCE 75.3m)
Interest Coverage Ratio = 5.71 (Ebit TTM 57.2m / Interest Expense TTM 10.0m)
EV/FCF = -3.50x (Enterprise Value 104.5m / FCF TTM -29.8m)
FCF Yield = -28.56% (FCF TTM -29.8m / Enterprise Value 104.5m)
FCF Margin = -5.50% (FCF TTM -29.8m / Revenue TTM 543.0m)
Net Margin = 9.27% (Net Income TTM 50.3m / Revenue TTM 543.0m)
Gross Margin = 85.96% ((Revenue TTM 543.0m - Cost of Revenue TTM 76.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 38.76%)
Tobins Q-Ratio = 0.10 (Enterprise Value 104.5m / Total Assets 1.05b)
Interest Expense / Debt = 2.57% (Interest Expense 2.38m / Debt 92.7m)
Taxrate = 47.92% (9.26m / 19.3m)
NOPAT = 29.8m (EBIT 57.2m * (1 - 47.92%))
Current Ratio = 5.91 (Total Current Assets 302.9m / Total Current Liabilities 51.2m)
Debt / Equity = 0.10 (Debt 92.7m / totalStockholderEquity, last quarter 884.5m)
Debt / EBITDA = 0.41 (Net Debt 29.6m / EBITDA 71.6m)
Debt / FCF = -0.99 (negative FCF - burning cash) (Net Debt 29.6m / FCF TTM -29.8m)
Total Stockholder Equity = 829.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.91% (Net Income 50.3m / Total Assets 1.05b)
RoE = 6.07% (Net Income TTM 50.3m / Total Stockholder Equity 829.1m)
RoCE = 6.37% (EBIT 57.2m / Capital Employed (Equity 829.1m + L.T.Debt 69.4m))
RoIC = 4.74% (NOPAT 29.8m / Invested Capital 628.7m)
WACC = 6.38% (E(87.1m)/V(179.8m) * Re(11.74%) + D(92.7m)/V(179.8m) * Rd(2.57%) * (1-Tc(0.48)))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.13%
Fair Price DCF = unknown (Cash Flow -29.8m)
EPS Correlation: 10.32 | EPS CAGR: 25.58% | SUE: -4.0 | # QB: 0
Revenue Correlation: -13.48 | Revenue CAGR: -33.12% | SUE: 0.25 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.45 | Chg30d=+0.060 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-1.04 | Chg30d=+0.025 | Revisions Net=+1 | Growth EPS=-196.9% | Growth Revenue=-0.2%